Notably, STAD is the only cancer type where the SLC7A11 expression is associated with these three markers for response to immunotherapy simultaneously, which highlighted the value for combined treatment of ferroptosis induction with immunotherapy in STAD. Here, SLC7A11 is linked to cancer.